Vivos Therapeutics (Vivos Therapeutics) Long-Term Capital Lease Obligation : $1.40 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Long-Term Capital Lease Obligation?

Vivos Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.40 Mil.

Vivos Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($1.64 Mil) to Dec. 2023 ($1.52 Mil) and declined from Dec. 2023 ($1.52 Mil) to Mar. 2024 ($1.40 Mil).

Vivos Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.30 Mil) to Dec. 2022 ($1.99 Mil) but then declined from Dec. 2022 ($1.99 Mil) to Dec. 2023 ($1.52 Mil).

Vivos Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Vivos Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Long-Term Capital Lease Obligation Chart

Vivos Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.30

1.99

1.52

Vivos Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.88	1.76	1.64	1.52	1.40

Vivos Therapeutics (NAS:VVOS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Vivos Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Therapeutics (Vivos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120

Website

https://www.vivos.com

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.

Executives

Ronald Kirk Huntsman	director, 10 percent owner, officer: Chairman & CEO	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman	officer: Chief Financial Officer	6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow	director	REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson	director	2 MUSICK, IRVINE CA 92618
Anja B Krammer	director	C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh	director, 10 percent owner, officer: Chief Medical Officer	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green	director	9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129